NASDAQ:NKTX

Nkarta (NKTX) Stock Price, News & Analysis

$7.56
+0.17 (+2.30%)
(As of 04/23/2024 ET)
Today's Range
$7.29
$7.82
50-Day Range
$7.29
$15.71
52-Week Range
$1.28
$16.24
Volume
710,252 shs
Average Volume
1.89 million shs
Market Capitalization
$373.62 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.83

Nkarta MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
135.9% Upside
$17.83 Price Target
Short Interest
Bearish
9.81% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$20 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.34) to ($2.30) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.78 out of 5 stars

Medical Sector

405th out of 910 stocks

Pharmaceutical Preparations Industry

181st out of 426 stocks

NKTX stock logo

About Nkarta Stock (NASDAQ:NKTX)

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

NKTX Stock Price History

NKTX Stock News Headlines

The only defense company you should be looking at
This is the ONLY defense company you should be watching right now.
The only defense company you should be looking at
This is the ONLY defense company you should be watching right now.
TD Cowen Reaffirms Their Buy Rating on Nkarta (NKTX)
Nkarta: NK Cell Therapy Advancement On Two Fronts
Nkarta Prices $240 Mln Offering; Stock Up Over 16%
Nkarta’s Strategic Focus and Financial Strength Underpin Buy Rating
NKTX Stock Earnings: Nkarta Beats EPS for Q4 2023
See More Headlines
Receive NKTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nkarta and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/21/2024
Today
4/23/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:NKTX
Fax
N/A
Employees
150
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$17.83
High Stock Price Target
$25.00
Low Stock Price Target
$15.00
Potential Upside/Downside
+136.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-117,500,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.56 per share

Miscellaneous

Free Float
46,649,000
Market Cap
$373.12 million
Optionable
Optionable
Beta
0.71
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Paul J. HastingsMr. Paul J. Hastings (Age 64)
    CEO, President & Director
    Comp: $938.41k
  • Dr. Alicia J. Hager (Age 54)
    Chief Legal Officer & Corporate Secretary
    Comp: $590.94k
  • Ms. Alyssa Levin C.A. (Age 39)
    CPA, Chief Financial & Business Officer and Principal Accounting Officer
  • Dr. Ralph Brandenberger Ph.D. (Age 55)
    Chief Technical Officer
  • Dr. James Trager Ph.D. (Age 61)
    Chief Scientific Officer
  • Mr. Greg Mann
    Vice President of Public Affairs and Investor Relations
  • Dr. David R. Shook M.D. (Age 46)
    Chief Medical Officer

NKTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Nkarta stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nkarta in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" NKTX shares.
View NKTX analyst ratings
or view top-rated stocks.

What is Nkarta's stock price target for 2024?

5 brokerages have issued 12-month price objectives for Nkarta's shares. Their NKTX share price targets range from $15.00 to $25.00. On average, they expect the company's stock price to reach $17.83 in the next twelve months. This suggests a possible upside of 135.9% from the stock's current price.
View analysts price targets for NKTX
or view top-rated stocks among Wall Street analysts.

How have NKTX shares performed in 2024?

Nkarta's stock was trading at $6.60 at the beginning of 2024. Since then, NKTX shares have increased by 14.5% and is now trading at $7.56.
View the best growth stocks for 2024 here
.

When is Nkarta's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our NKTX earnings forecast
.

How were Nkarta's earnings last quarter?

Nkarta, Inc. (NASDAQ:NKTX) issued its quarterly earnings data on Thursday, March, 21st. The company reported ($0.57) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.62) by $0.05.

What other stocks do shareholders of Nkarta own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nkarta investors own include Axcella Health (AXLA), Cronos Group (CRON), Block (SQ), Advanced Micro Devices (AMD), ASML (ASML), Beyond Meat (BYND), Citigroup (C), Salesforce (CRM), CVS Health (CVS) and DraftKings (DKNG).

When did Nkarta IPO?

Nkarta (NKTX) raised $150 million in an initial public offering on Friday, July 10th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. Cowen, Evercore ISI, Stifel and Mizuho Securities served as the underwriters for the IPO.

Who are Nkarta's major shareholders?

Nkarta's stock is owned by a number of retail and institutional investors. Top institutional investors include Wasatch Advisors LP (2.36%) and Denali Advisors LLC (0.05%). Insiders that own company stock include David Shook, Dawn N Edwards, James Trager, Kanya Rajangam, Nadir Mahmood, Paul J Hastings, Paul J Hastings, Ra Capital Management, LP, Ralph Brandenberger and Simeon George.
View institutional ownership trends
.

How do I buy shares of Nkarta?

Shares of NKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NKTX) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners